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Fragile X syndrome (FXS) is caused by the absence of the Fragile X
Mental Retardation Protein (FMRP) in neurons. In the mouse, the
lack of FMRP is associated with an excessive translation of hundreds
of neuronal proteins, notably including postsynaptic proteins. This
local protein synthesis deregulation is proposed to underlie the
observed defects of glutamatergic synapse maturation and function
and to affect preferentially the hundreds of mRNA species that were
reported to bind to FMRP. How FMRP impacts synaptic protein
translation and which mRNAs are most important for the pathology
remain unclear. Here we show by cross-linking immunoprecipitation
in cortical neurons that FMRP is mostly associated with one unique
mRNA: diacylglycerol kinase kappa (Dgkκ), a master regulator that
controls the switch between diacylglycerol and phosphatidic acid
signaling pathways. The absence of FMRP in neurons abolishes
group 1 metabotropic glutamate receptor-dependent DGK activity
combined with a loss of Dgkκ expression. The reduction of Dgkκ
in neurons is sufficient to cause dendritic spine abnormalities, syn-
aptic plasticity alterations, and behavior disorders similar to those
observed in the FXS mouse model. Overexpression of Dgkκ in
neurons is able to rescue the dendritic spine defects of the Fragile
X Mental Retardation 1 gene KO neurons. Together, these data
suggest that Dgkκ deregulation contributes to FXS pathology and
support a model where FMRP, by controlling the translation of
Dgkκ, indirectly controls synaptic proteins translation and mem-
brane properties by impacting lipid signaling in dendritic spine.
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Fragile X syndrome (FXS), the most common cause of inheritedintellectual disability and autism, is due to the transcriptional
inactivation of the Fragile X Mental Retardation 1 gene (FMR1)
(1, 2). The FMR1 knockout (KO) mouse (Fmr1−/y) replicates
phenotypes similar to human symptoms—including autistic-like
behaviors, cognitive deficits, and hyperactivity—as well as ab-
normal dendritic spine morphology (3). FMR1 encodes Fragile X
Mental Retardation Protein (FMRP), an RNA-binding protein
associated to polyribosomes and involved in the translational
control of mRNAs important for synaptic plasticity (4). Consistent
with a posttranscriptional function, the absence of FMRP in
Fmr1−/y mouse causes abnormal signaling of group 1 metabotropic
glutamate receptors (mGluRI), leading to several forms of abnor-
mal synaptic plasticity that rely on protein translation (5, 6). Protein
expression analyses confirmed a role of FMRP in neuronal trans-
lational control (7), but the extent of this control remains unclear.
Although several studies focusing on individual mRNA targets (e.g.,
Fmr1, Map1b, Psd95, App, etc.) suggest specific control by FMRP
(2), studies of global translation, including in vivo labeling in the
Fmr1−/y mouse (8), showed thousands of neuronal proteins
deregulated in the absence of FMRP, pointing toward a general
translational derepression. Studies seeking to identify the tran-
scripts controlled by FMRP identified candidate mRNAs num-
bering in the hundreds to thousands (9–13). The lack of obvious
overlap between several of these candidate lists calls into ques-
tion the RNA binding specificity of FMRP (13). How FMRP
controls the translation of hundreds of distinct proteins, whether
by direct mRNA binding or in an mRNA-independent manner
[e.g., through its direct binding with the ribosome (14)], is still
unclear. With these hundreds of potential target mRNAs, an-
other key question still awaits an answer: Are there specific
mRNAs whose deregulation matters the most for the pathology?
Cross-linking immunoprecipitation (CLIP) is a powerful tech-
nique to capture the cognate targets of RNA binding proteins (15).
Intriguingly, prior CLIPs on FMRP showed rather modest overlaps
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(13). Whether influenced by the choice of starting material (brain
extracts vs. nonneuronal proliferating cells) or the experimental con-
struction (endogenous vs. tagged protein; whole cell content vs. sub-
cellular fraction; etc.), these studies focused more on determining the
binding motives rather than on identifying all of the mRNA species
bound to FMRP. Using a CLIP strategy in mouse cortical neurons
that preserves the integrity of mRNAs and comparing the RNAs
immunoprecipitated in Fmr1+/y vs. Fmr1−/y extracts, we find that
FMRP mostly associates with a single mRNA species. This transcript
encodes diacylglycerol kinase kappa (Dgkκ), a member of the master
regulator DGK family. Dgkκ acts as a spatiotemporal switch between
the diacylglycerol (DAG) and phosphatidic acid (PA) signaling path-
ways, downstream of mGluRI and upstream of general translation
activation control. Our data reveal that the deregulation of mGluRI-
dependent DGK activity is a substantial contributor to FXS symptoms
observed in the mouse model, one that can explain the paradoxical
global protein synthesis deregulation observed in Fmr1−/y neurons.
Results
FMRP Associates with One Main mRNA Species in Mouse Cortical Neurons,
Dgkκ mRNA. To identify the mRNAs associated with FMRP, we
performed a CLIP approach on dissociated cortical neurons. To
control for cross-reaction of anti-FMRP antibodies to other RNA-
binding proteins (such as the FMRP paralogs FXR1P or FXR2P),
we performed the CLIP both on neurons from wild-type (Fmr1+/y)
and Fmr1 KO (Fmr1−/y) mice (Fig. S1 A–C). (All raw data of the
figures can be provided upon request.) The H120 polyclonal anti-
FMRP antibody was used based on its ability to efficiently immu-
noprecipitate FMRP (Fig. S1D) together with several mRNAs
considered as validated FMRP targets (e.g., Dlg4, Map1b,
CamK2a, and Arc), in comparison with mRNAs considered as
non-FMRP targets (PO, Glrb, ActB, and 28S) (Fig. S1E). Because
prior CLIP-sequencing studies did not identify the G-quadruplex
motif, the highest affinity binding motif known for FMRP (11, 12),
we kept the RNAs intact to perform random reverse transcription
followed by microarray so that GC-rich or other sequencing-resistant
motives would not impede the mRNA identification. Aside from
Fmr1 itself (whose mRNA expression is prevented by the KO de-
sign), only two genes showed significantly altered expression when
comparing the total RNA levels from Fmr1+/y and Fmr1−/y neurons:
Apol7c and Tmsb15l (Dataset S1). Both transcripts showed an ap-
proximate twofold reduction in Fmr1−/y neurons, and neither has an
obvious link to FXS, indicating that a loss of FMRP has virtually no
impact on the whole transcriptome profile of neurons. Among 28,853
interrogated transcripts, 596 are enriched by CLIP in Fmr1+/y
compared with Fmr1−/y neurons (as scored by enrichment in Fmr1+/y
compared with Fmr1−/y extracts, relative to input amounts; Fig. 1 A
and B) at a P value ≤ 0.05 compared with 298 transcripts that are
depleted (Fig. 1A). This difference increases exponentially with de-
creasing P value (Fig. 1B), confirming the FMRP specificity of the
approach. More than 20% (126 of 596) of the CLIP-identified
transcripts have been identified in the previous study by Darnell
et al. (11) (Fig. S1F). Of the 596 CLIP-identified transcripts, only
7 mRNAs are enriched by more than twofold. The remaining
transcripts have CLIP efficiencies that are thus mostly resulting from
nonspecific binding. Dgkκ mRNA strikingly stands out as the sole
mRNA with a CLIP efficiency well above any other mRNA. Con-
sistent with this observation, all 27 microarray probe sets covering
Dgkκ mRNA show a high CLIP signal, indicating that Dgkκ mRNA
is cross-linked to FMRP as an entire 8.2-kb transcript (Fig. S1G).
The results of the microarrays were confirmed by quantitative RT-
PCR (qRT-PCR) for Dgkκ and 42 other RNAs, including the RNAs
with next-best high CLIP score (Tln2, Ppfia3, Ogdh, Apc, etc.) and
previously proposed as targets (11, 12) (Dlg4,Camk2a,Agap2, Shank3,
etc.) (Fig. 1C). Comparison of CLIP efficiencies by microarray and by
qRT-PCR for these 43 RNAs shows that Dgkκ is by far the mRNA
most efficiently and reproducibly coimmunoprecipitated with anti-
FMRP H120 in cortical neurons (Fig. 1D). Apart from Dgkκ, 10% of
the other tested mRNAs (10 of 42) have CLIP efficiencies that are
consistent between the microarray and qRT-PCR data. The variability
in CLIP efficiency of the remaining mRNAs is probably a result of
their weak interaction or cross-linking efficiency with FMRP. To
control that the CLIP was not biased by the antibody used, we
repeated it with validated 7G1-1 antibody (9). Again, the com-
parison of Dgkκ CLIP efficiency with that of 14 different mRNAs,
including mRNAs previously established as target (APC, Map1B,
Dlg4, etc.) as well as “negative”mRNAs (Actb, 28S, etc.), shows that
Dgkκ is the mRNA with the strongest CLIP efficiency for FMRP
(Fig. S1H).
To determine whether the FMRP–Dgkκ mRNA interaction
revealed by the CLIP approach was due to a cross-linking artifact,
we analyzed the interaction between FMRP andDgkκ mRNA by in
vitro binding assays. Human His-tagged FMRP binds to a FMR1
mRNA fragment (N19) with the highest affinity known previously
(12, 16) (Fig. 2A). Dgkκ transcript easily displaces FMR1 mRNA
fragment N19, contrary to nonspecific RNAs (antisense Dgkκ
transcript) or RNAs with lower CLIP efficiency (Dlg4) (Fig. 2A).
These data indicate that human FMRP binds to mouse Dgkκ
mRNA with the highest affinity currently identified compared
with any other transcript.
FMRP Positively Controls Dgkκ Translation.We developed a polyclonal
antibody against Dgkκ and validated it using Dgkκ expressing vector
in COS cells (Fig. S2A). Remarkably, in dissociated cortical neurons
[7 days in vitro (DIV)], the main protein product detected by the
antibody is severely reduced in absence of FMRP (Fig. 2B). These
data suggest that FMRP is required for the effective translation of
Dgkκ mRNA. To confirm an impact of the absence of FMRP on
Dgkκ translation in brain, we analyzed the profile of Dgkκ mRNA
in mouse brain polysomes using qRT-PCR. In Fmr1+/y brain
extracts, Dgkκ mRNA is primarily associated with light and heavy
polysomes, consistent with a normal translation rate (Fig. 2C). By
contrast, in Fmr1−/y extracts, Dgkκ mRNA is less present in poly-
somal fractions and more present in monosomal fractions, whereas
the distribution of other tested mRNAs Dlg4 and Map1b is not
altered. These data are in agreement with an impairment of Dgkκ
translation in absence of FMRP.
DGK Activity Is Deregulated in the Absence of FMRP. Dgkκ converts
DAG into PA (Fig. 2D). We assessed PA and DAG levels in
dissociated cortical neurons using a liquid chromatography coupled
to tandem mass spectrometry (LC-MS/MS) lipidomics approach.
PA profiling using multiple reaction monitoring (MRM) MS/MS
mode revealed three major PA species (Fig. S2C), namely, 36:1,
38:1, and 38:2. PA level is maintained at low levels in cells by
the activity of potent lipid phosphate phosphohydrolase (17), but
increases rapidly in neurons on activation of mGluRs and its
G protein-coupled phospholipase C, immediately upstream of DGKs
(18). Indeed, a brief application of group 1 mGluR (mGluRI)
agonists (S)-3,5-dihydroxyphenylglycine (DHPG; 10 min; 100 μM)
(Fig. S2D) or L-quisqualic acid (Quis; 10 min; 5 μM) (Fig. 2E)
increased 36:1, 38:1, and 38:2 PAs by 40% ± 4%, 18% ± 5%, and
40% ± 6%, respectively. Quis has a more robust action than
DHPG as indicated by ERK1/2 phosphorylation (Fig. S2B) and
was chosen for the rest of the experiments. The mGluR-dependent
increase of PAs depends on DGK activity because a pretreatment
with DGK-specific inhibitors R59022 and R59949 (19) prevents
the effect (Fig. 2E, Quis+R). In unstimulated Fmr1−/y neurons, PA
levels are not significantly different from in Fmr1+/y neurons (Fig.
2F). In Quis-stimulated Fmr1−/y neurons, the increase of PA seen
in Fmr1+/y neurons was lost (Fig. 2F), indicating that the Quis-
dependent DGK activation requires FMRP. To determine whether
the PA synthesis defect could be due to an alteration upstream
of the DGK activity, we analyzed DAG levels in Fmr1+/y and
Fmr1−/y neurons (Fig. 2G). In unstimulated neurons, an increase of
60.8% ± 10% of total DAG was observed in the Fmr1−/y compared
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with Fmr1+/y neurons. This increase affected most major DAG
species (Fig. S2E). Upon Quis stimulation, a similar increase of
total DAG level in Fmr1+/y and Fmr1−/y neurons indicated that the
absence of FMRP does not impair DAG synthesis. Together, these
data indicate that the defect of Quis-dependent PA synthesis and
the excess of DAG observed in Fmr1−/y neurons is due to a loss of
DGK activity. To test whether a loss of DGK activity could be
detected in humans, we analyzed postmortem cerebellar extracts of
Fig. 1. FMRPmostly targetsDgkκ mRNA inmurine cortical neurons. (A) Volcano plot representation of the FMRP CLIP-microarray results. The x axis is log2 of fold change
of average intensity for each individual dataset (AI) from Fmr1+/y immunoprecipitated samples relative to Fmr1+/y total RNA input compared with Fmr1−/y immunopre-
cipitated samples relative to Fmr1−/y total RNA input [i.e., Log2([AIWt CLIP/AIWt Input]/[AIKO CLIP/AIKO Input])]. The y axis is −log(P value) with P value determined by using the
significance analysis of microarrays test (Materials andMethods) with n = 5 (i.e., one microarray per independent CLIP experiment per biological replicate). The name of a
few mRNAs with high P value or previously proposed as targets is given, and the arbitrary 0.05 P value thresholds with corresponding number of genes are shown.
(B) Representation of CLIP-identified transcripts number as a function of the P value determined as in A. (C, Upper) qRT-PCR validation of immunoprecipitated mRNAs.
Data are fold changes of CLIP efficiency of 43 RNAs chosen among the best immunoprecipitated mRNAs (Dgkκ, Tln2, Ppfia3, Ogdh, Apc, etc.) or previously proposed as
targets (Dlg4, Camk2a, Agap2, Shank3, etc.) or non-FMRP targets (RplP0, Actb, 18S, and 28S) determined by qRT-PCR using the ΔΔCT method ([CTWt CLIP − CTWt Input] −
[CTKO CLIP − CTKO Input]). Data are means ± SD. *P ≤ 0.05 (unpaired t test, n = 4 biological replicates). (C, Lower) Absence of differential expression of the 43 RNAs between
Fmr1+/y and Fmr1−/y neuron extracts. Fold change of expression was calculated with ΔΔCTmethod with Rplp0 or ActB as normalizer. (D) Scatter plot representation of the
fold change of clip efficiency of the 43 RNAs as in C, determined by microarray vs. by qRT-PCR (Left) and of their P value (Right); gray zones indicate >0.05 P value.
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FXS patients, the cerebellum being a region of the brain affected
by FXS (20). Remarkably, an excess of DAG is observed in the
FXS compared with the nonaffected samples (Fig. 2H).
Dgkκ Loss of Function Reproduces FXS-Like Phenotype.Dgkκ mRNA
is expressed throughout the brain (Fig. S3A), but its involve-
ment in synaptic plasticity was unknown. We focused on the
Fig. 2. FMRP positively controls Dgkκ expression. (A) Gel shift assay competition to determine the relative binding strength of FMRP for Dgkκ mRNA.
32P-labeled Fmr1 N19 mRNA fragment was incubated with His-FMRP Iso7 (0.1 pmol) in the presence of increasing concentrations of indicated unlabeled
competitor RNAs. Lane 0, control without protein; lane C, control without competitor RNA; numbers are log of competitor RNA concentrations. The graph depicts the
fraction of bound labeled N19 RNA plotted against unlabeled competitor RNA concentration. Data are means ± SD, n = 3. (B) Western blot analysis with indicated
primary antibodies in cortical neuron extracts. Lanes 1–6 indicate biological replicates for the corresponding genotypes. The molecular mass of protein markers is
indicated (kDa). (C) Brain polysome profile from 10-d-old mice shows decreased ribosome loading forDgkκ mRNA in the absence of FMRP. qRT-PCR analysis (expressed
as percent of total fractions) reveals an increased amount of Dgkκ mRNA in monosomal fractions and decreased amount in polysomal fractions in Fmr1−/y compared
with Fmr1+/y brain extracts, but no major change in Dlg-4 or Map1b mRNAs (data are means of two biological replicates with two technical replicates). (D) DGKs
convert DAG into PA. (E) Bar diagram showing relative PA levels in dissociated cortical neurons. Measurements were made by LC-MS/MS, MRM mode on total lipid
extracts from Fmr1+/y and Fmr1−/y murine cortical neurons (8 DIV). The level of the three major PAs (36:1, 38:1, and 38:2) is shown in basal conditions (NT), after mGluRI
activation with Quis treatment, 5 μM 10 min (+Quis), and after 15 min DGK inhibitors 3 μM R59022 and 0.2 μM R59949 at 6 μM prior Quis 5μM 10 min (+Quis+R).
Values are relative to the untreated samples. A.U., arbitrary units. n = 5. ***P < 0.001 (unpaired t test); ns, nonsignificant. Data are means ± SD. (F) Bar diagram
showing relative PA levels in untreated Fmr1+/y and Fmr1−/y cortical neurons and after treatment with Quis 5 μM 10 min (+Quis). ***P < 0.001, **P < 0.01; n = 5.
(G) Bar diagram showing relative total DAG levels in cortical neurons. Measurements were made with LC-MS/MS on total lipid extracts from Fmr1+/y and Fmr1−/y
cortical neurons (8 DIV) in basal conditions (NT) and after Quis treatment 5 μM 10 min (+Quis). ***P < 0.001, n ≥ 3. (H) Bar diagram showing relative total DAG
levels in normal (ctr) and fragile X (FXS) human postmortem cerebellum extracts. Measurements were made as in G. **P < 0.01 (unpaired t test, n = 4 biological
replicates with technical replicates).
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well-characterized CA1 region of mouse hippocampus. We per-
formed Dgkκ silencing in organotypic slices with a validated
shRNA (Fig. S3 B–D). We examined the effect of Dgkκ silenc-
ing on long-term potentiation (LTP) and long-term depression
(LTD), two forms of synaptic plasticity that are altered in Fmr1−/y
mice (5, 21, 22). Theta burst stimulation (TBS)-induced LTP at
Schaffer collateral-CA1 region was reduced with shRNA–Dgkκ
(112% ± 3% at 30–40 min, instead of 135% ± 6% with shRNA–
scramble) (Fig. 3A), whereas low-frequency stimulation-induced
LTD was increased (83% ± 3% at 30–40 min, instead of 95% ± 3%
with shRNA–scramble) (Fig. 3B). These data indicate that the re-
duction of Dgkκ in CA1 neurons induces synaptic plasticity alter-
ations. Remarkably, these alterations are similar to the one
observed in FXS mouse model (6). Approximately 50% of patients
with FXS also carry an autism diagnosis, and recent research on
hallmark autistic symptoms point toward striatal dysfunction (23,
24). To test whether Dgkκ loss of function could contribute to FXS
phenotype, AAV9-delivered shRNA–Dgkκ was injected bilaterally
into the striatum of wild-type mice. Injected mice were submitted
for behavioral testing to assess autism-like behaviors, cognitive
impairments, and hyperactivity, the most frequent FXS pheno-
types. Four weeks after injection, shRNA expression was broadly
spread across the striatal regions (Fig. 4A and Fig. S4 A–C).
Consistent with autistic phenotype, animals expressing shRNA–
Dgkκ show deficient social interaction, altered nest-building
behavior, and spontaneous motor stereotypies compared with
mice expressing shRNA–scramble (Fig. 4 B–D and Fig. S4
D–G), all striatal-dependent symptoms observed in Fmr1−/y
mice (25–28). Stereotypic behavior is indicated by an en-
hanced learning on the accelerating rotarod (24), mainly at late
stages of learning (Fig. 4E). In the novel object recognition (NOR)
test, shRNA–Dgkκ-expressing mice showed repetitive patterns of
exploration, evocative of cognitive inflexibility, but no detectable
memory impairment (Fig. 4F). The absence of memory impair-
ment in these animals, in contrast with Fmr1−/y mice, is a likely
consequence of a striatal-centered shRNA expression, sparing cor-
tices and hippocampus. Finally, shRNA–Dgkκ-expressing animals
were hyperactive, crossing quadrants more frequently during
NOR testing and traveling longer distances in activity boxes
(Fig. 4G). Together, these data indicate that animals with striatal
silencing of Dgkκ mimic autistic and hyperactivity symptoms
and recapitulate the core neurologic phenotypes observed in
Fmr1−/y mice.
Finally, we examined the impact of Dgkκ loss of function on
dendritic spine morphology and dynamics.Dgkκ silencing in the CA1
region of mouse hippocampus organotypic slices caused a strong
increase of abnormally long and multiheaded spines and a marked
decrease of the proportion of mature spines (Fig. 5 A–E), whereas
spine density remained unchanged (Fig. 5C). Additionally, there was
a significant increase of spine turnover, as indicated by the increased
rate of spine formation and elimination, associated with spine in-
stability in Dgkκ silenced neurons (Fig. S5 A–C). These data in-
dicate that Dgkκ is necessary for spine maturation and maintenance
and that its loss leads to structural defects similar to those previously
observed in the Fmr1−/y mice (29, 30). To establish a functional link
between Dgkκ and FMRP, we tested whether the overexpression of
Dgkκ within Fmr1−/y neurons could rescue the dendritic spine
phenotype. Remarkably, Fmr1−/y neurons transfected with plas-
mid expressing Dgkκ had their spine defects corrected (Fig. 5
A–F, Fmr1−/y+Dgkκ), indicating that Dgkκ overexpression is
able to compensate for the lack of FMRP.
Discussion
Based on a CLIP analysis of FMRP-bound mRNAs, we provide
evidence that Dgkκ mRNA is a primary target of FMRP in cortical
neurons. Surprisingly, although previous analyses have identified
hundreds of potential FMRP-binding mRNA candidates, Dgkκ
mRNA was not identified (9–12). Although we have no definitive
answer as to why Dgkκ was not discovered before, several expla-
nations can be proposed. First, it should be noted that Dgkκ was
identified in 2005 (31); thus, it could not have been identified by
initial microarray studies. A second factor is the starting biological
material. Although we used pure neuron cultures, Ascano et al.
(12) performed CLIP in kidney cells where Dgkκ may have been
missed easily because its expression is 100-fold lower in kidney than
in neuronal tissues (Fig. S3E). Darnell et al. performed CLIP on
brain homogenate where Dgkκ should have appeared. However,
whether Dgkκ CLIP efficiency is lower in brain homogenates
compared with neuron cultures or whether Dgkκ was lost during
the purification step of brain polyribosomes (performed to reduce
the high complexity of whole brain extracted material) remains to
be determined. Another factor is the bioinformatics treatment of
data because Dgkκ suffers from database annotation problems.
Human DGKκ is annotated as a noncoding gene in genome build
37 (GRCh37) (this error has been corrected in GRCh38), and
mouse Dgkκ lacks exon 1 (noted as unsequenced). These problems
may have screened out Dgkκ during the bioinformatics analyses.
Finally, other factors may have been critical for identification of
Dgkκ. First, as explained in results, we kept mRNAs intact in cases
where structured regions are difficult to amplify. Second, we nor-
malized mRNA targets both to the input (to avoid problem of
expression level) and to the signal from Fmr1−/y littermates (to
reduce the noise of unspecific binding). Finally, we quantified results
both by microarrays and qPCR.
Our CLIP also identified another 595 mRNAs as significantly
associated with FMRP (Fig. 1A). The lower and more variable
CLIP efficiency of most of these mRNAs compared with Dgkκ
suggests that they are occasional rather than bona fide interactors.
How FMRP specifically interacts with Dgkκ mRNA remains to
be defined. None of the previously proposed motives bound by
FMRP could be evidenced in Dgkκ (e.g., Dgkκ does not contain
motifs that would readily establish a G-quadruplex structure).
However, Dgkκ mRNA is highly conserved from mouse to hu-
man, with 77% nucleotide identity for coding regions and 68%
for UTRs. Furthermore, the FMRP binding site is apparently
sufficiently conserved to allow cross-species interaction between
human FMRP and mouse mRNA (Fig. 2A). It will be important to
define whether a specific RNAmotif exists inDgkκ mRNA specifying
FMRP binding. In contrast with most of its previous character-
ized targets, FMRP positively controls Dgkκ translation (Fig. 2 B
and C). How FMRP can stimulate Dgkκ translation is the next
pending question. The alleviation of a miRNA repression, such
as the one identified for FXR1, is a possibility (32). Upon
identification of Dgkκ mRNA as a main interactor of FMRP, we
focused our analysis on the biological significance of a Dgkκ
deregulation in FXS Fmr1−/y mouse model. Dgkκ is a member of
the DGK isozymes, master regulators of the balance between
DAG and PA signaling (31). Several DGKs have been shown to
be involved in structural and synaptic plasticity control (33–36),
but no data were available onDgkκ neuronal function. We identified
Fig. 3. Synaptic alterations induced by interference with Dgkκ expression.
(A) Decrease in LTP in slice cultures infected with shRNA–Dgkκ (n = 7) vs. shRNA–
scramble (n = 6) expressing AAV viruses. *P < 0.05 (two-way ANOVA). (B)
Increase in LTD in slice cultures infected with shRNA–Dgkκ (n = 7) vs. shRNA–
scramble (n = 6) expressing AAV viruses. *P < 0.05 (two-way ANOVA).
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that the absence of FMRP leads to the deregulation of mGluRI-
dependent DGK activity, causing perturbations in the balance
between its substrate, DAG, and its product, PA. These two second-
messengers signal via many pathways in a spatiotemporally
coordinated manner. DAG signals trafficking, secretion, and
cytoskeletal reorganization by binding and activating C1 domain-
containing proteins in neuronal and immune tissues. These pro-
teins include PKC isozymes, PKD, chimaerins, Unc13, and RasGRP
(37, 38). PA signals cell growth by interacting with many effectors
(e.g., mTOR, PAK1, PIP5K, PKCe, sphingosine kinase, Raf1,
etc.). Both DAG and PA trigger general protein translation
through the allosteric activation of their many effectors; their
physiologic concentrations are thus critical for normal protein
translational control.
We showed that DAG level is increased in nonstimulated
Fmr1−/y neurons, as well as in human FXS cerebellum, suggest-
ing that an excessive DAG signaling occurs in FXS. PKCa, one
main DAG effector (39), has been shown to be strongly activated
in Fmr1−/y mouse brain (40). One direct consequence of PKC
activation in cells is an activation of general translation (41). The
perturbation of DAG level could thus explain the excess of
translation observed in Fmr1−/y neurons. Furthermore, PKCs
have been shown to exert control over sensitization status of
mGuRI-LTD by controlling the p38 MAPK pathway (42), and
mGluRI-LTP in widespread areas of the brain (39). Thus, PKCs
could be an important factor in FXS synaptic plasticity deregulation.
We also showed that the mGluRI-dependent PA synthesis is
abolished in Fmr1−/y neurons. This finding indicates a transient
deficit in PA signaling. Among PA effectors, mTOR is proposed to
be abnormally activated in Fmr1−/y mice (43). mTOR signaling
regulates translation initiation; however, the deregulation of this
pathway does not seem to be the cause of increased protein synthesis
because its inhibition does not rescue the excess of translation (44).
How the mTOR pathway is precisely deregulated remains unclear.
Previous observations indicated that DAG triggers dendritic
spine growth and destabilization, whereas PA is spine-stabilizing,
indicating that synaptic levels of DAG and PA in neurons are
determinants of the dendritic spine growth and stability (45).
Thus, an increase of DAG and a lack of PA are expected to
produce an increase in spine growth and a defect of spine mat-
uration. This scenario is exactly what we observed in Fmr1−/y
neurons. By controlling the switch between DAG and PA sig-
naling, DGK activity is a key regulator of spine maintenance.
Remarkably, besides Dgkκ, nine other DGK isozymes exist, but
Fig. 4. Interference with Dgkκ expression in the striatum leads to FXS-like behavior. (A) Representative distribution of GFP 4 wk after stereotaxic AAV
injection shows striatum-centered shRNA expression, sparing cortices and hippocampus. Coordinates refer to Bregma. CPu, caudate putamen; h, hippo-
campus; NAc, nucleus accumbens. (B) Mice expressing shRNA–Dgkκ (sh-Dgkκ) show decreased time spent in social contact, due notably to diminished number
and duration of nose contacts compared with shRNA–scramble (sh-scrbl)-expressing mice (n = 16 per AAV treatment). ***P < 0.001 (one-way ANOVA).
(C) Mice expressing shRNA–Dgkκ (sh-Dgkκ) fail to build proper nests. ***P < 0.001 (Kruskal–Wallis ANOVA). (D) Mice expressing shRNA–Dgkκ (sh-Dgkκ) display
spontaneous stereotypic grooming episodes and head shakes. **P < 0.01; (one-way ANOVA). (E and F ) Consistent with stereotyped behavior, sh-Dgkκ−
injected animals show facilitated motor skill learning on the accelerated rotarod (E ) and repetitive patterns of exploration in the NOR test, associated
with increased locomotor activity as measured by the number of quadrant crossings (F ). **P < 0.01 (E; three-way repeated measure ANOVA); ***P < 0.001
(F; two-way repeated measure ANOVA with Newman–Keules posttest). (G) Hyperactivity is confirmed in activity boxes, where mice bearing a striatal
knockdown of Dgkκ travel a longer distance over 60 min compared with shRNA–scramble-expressing animals. **P < 0.01 (two-way repeated-measure
ANOVA). Data are means ± SEM.
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only Dgkκ mRNA is targeted by FMRP (Dataset S1). DGK
deficiencies cause an imbalance between DAG and PA and af-
fect cellular signaling (45). DGKs are mostly expressed in the
brain, where (for those that have been studied) they influence
dendritic spine morphology and synaptic plasticity (46, 47). The
role of each DGK seems to differ based on its distinct localiza-
tion or structure, suggesting that each has evolved specialized
functions. It will be important to better define the specificity of
each of these critical enzymes.
We showed that the reduction of Dgkκ expression in striatal
areas of mouse brain reproduced the hyperactive and autistic-like
behaviors similar to FXS and that the silencing of Dgkκ reproduces
both morphological and functional spine abnormalities of Fmr1−/y
mouse model. These results emphasize that Dgkκ is involved in the
molecular basis of mGluRI-controlled mammalian synaptic plas-
ticity, the deregulation of which accounts for several of the main
neurological phenotypes found in FXS. Remarkably, the over-
expression of Dgkκ within Fmr1−/y neurons rescued their spine de-
fects, demonstrating the functional link between FMRP and Dgkκ
activity.
The identification of the master-regulator Dgkκ as a main
mRNA target of FMRP enables us to propose a novel molecular
mechanism driving neuronal defects in the FXS mouse model.
Instead of repressing general synaptic translation (the current
proposed model), our data support a different model where
FMRP is mostly dedicated to the positive control of Dgkκ. The
defective regulation of Dgkκ in the absence of FMRP explains
the dendritic spines and synaptic plasticity alterations observed
in FXS. The increased level of DAG seen in Fmr1−/y unstimu-
lated neurons would be a main triggering factor of the general
local increase of synaptic protein synthesis seen in FXS neurons
(e.g., by activating PKCs or other effectors) and the induction of
abnormal spine growth. The lack of PA synthesis after mGluR
activation, conversely, could be responsible for the defect in spine
maturation and associated perturbations of synaptic plasticity via
the failure to activate its numerous binding effectors (e.g., mTOR)
and by impacting actin polymerization. Currently proposed thera-
peutic approaches mostly target the excess of protein synthesis ob-
served in FXS neurons. Our present data suggest that this strategy
may be insufficient: The defect of spine maturation that results from
defective PA signaling and its associated lipid membrane alterations
should be considered as well. DGK activity may represent a prom-
ising and novel therapeutic target.
Materials and Methods
Ethics Statement.Animal work involved in this studywas conducted according
to relevant national Comité National de Réflexion Ethique en Expérimen-
tation Animale and international guidelines (86/609/CEE).
Primary Cortical Neuron Cultures. Cortices from C57BL/6J Fmr1+/y or Fmr1−/y mouse
embryos (48) [embryonic day (E17.5)] were dissected in 1× PBS, 2.56 mg/mL
D-glucose, 3 mg/mL BSA, and 1.16 mM MgSO4; incubated for 20 min with
0.25 mg/mL trypsin and 0.08 mg/mL DNase I; and mechanically dissoci-
ated after supplementation of medium with 0.5 mg/mL trypsin soybean
inhibitor, 0.08 mg of DNase I and 1.5 mM MgSO4. The cells were plated on
poly-L-lysine hydrobromide-coated six-well culture plates for 8 d in Neuro-
basal Medium (GIBCO) supplemented with B27, penicillin/streptomycin, and
0.5 μM L-glutamine.
CLIP on Primary Neurons. CLIP strategy was adapted from Ule et al. (15) with
modifications for neuron cultures. Neurons from Fmr1+/y or Fmr1−/y mice
grown in six-well plates for 8 DIV were gently washed with cold PBS and
exposed to 254-nm UV (400 mJ/cm2, in Stratalinker 2400) on ice. Neurons
from three littermate embryos with the same genotype were pooled (con-
stituting one biological sample) and lysed with 1 mL of lysis buffer [50 mM
Tris·HCl, pH 7.4, 100 mM KCl, 1 mM MgCl2, 0.1 mM CaCl2, 0.1% SDS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 30 U of anti-RNase (Ambion), and
10 U of DNase Turbo (Invitrogen)] for 5 min at 37 °C. Lysates were spun
down at 18,000 × g at 4 °C, and supernatants were precleared by incubation
with 50 μL of free Dynabeads protein G (Dynal) and then on 50 μL of
Dynabeads protein G coupled to rabbit anti-mouse IgGs (5 μg) for 1 h each.
The lysates were then incubated overnight with agitation on 50 μL of
Dynabeads protein G coupled to 5 μg of anti-FMRP antibody (H-120; Santa
Cruz). After immunoprecipitation, the supernatants were saved for RNA
extraction (Fmr1+/y and Fmr1−/y “inputs”), and the beads were washed three
times with 1 mL of high-salt washing buffer (50 mM Tris·HCl, pH 7.4, 1 M KCl,
1 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS;
4 °C). RNAs from Fmr1+/y and Fmr1−/y neurons were recovered by treatment
of the beads with 0.4 mg of proteinase K in buffer (100 mM Tris·HCl, pH 7.4,
Fig. 5. Dendritic spine alterations and rescue with Dgkκ expression modulation. (A) Illustration of the changes in spine morphology in Fmr1−/y (Left) or
Fmr1−/y (Right) CA1 pyramidal neurons transfected with pAAV-EGFP-shRNA-scramble (Upper Left), pAAV-EGFP-shRNA-Dgkκ (Lower Left), pAAV-EGFP
(Upper Right), and pAAV-Dgkκ (Lower Right). Note the presence of multiheaded spines (stars) as well as very long thin spines (arrows). (Scale bar: 2 μm.)
(B) Spine changes (new spines, +, and lost spines, −) occurring in shRNA– scramble-expressing pyramidal neurons. (Scale bar: 2 μm.) (C) Absence of changes
in spine density under the four conditions. ns, not significant. (D) Increase in multihead spines and decrease in mature spines (stubby-mushroom) in shRNA–
Dgkκ (sh-Dgkκ) (n = 10) vs. shRNA–scramble (sh-scrbl) transfected cells (n = 8) and in Fmr1−/y (n = 9) vs. Fmr1−/y+Dgkκ transfected cells (n = 8). *P < 0.05;
**P < 0.01; ***P < 0.001 (two-way ANOVA with Bonferroni posttest). (E ) Distribution of spine length in shRNA–Dgkκ (n = 342 spines), shRNA–scramble (n =
297 spines), Fmr1−/y (n = 359 spines), and Fmr1−/y+Dgkκ (n = 377 spines) transfected cells (P = 0.13, Kolgomorov–Smirnov test). (F) Decrease in spine stability
over time. *P < 0.05 (two-way ANOVA with Bonferroni posttest).
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50 mM NaCl, and 10 mM EDTA) for 20 min at 37 °C. The H120 polyclonal anti-
FMRP antibody was selected among several tested antibodies (7G1.1; IC3) based
on its ability to immunoprecipitate efficiently some mRNAs considered as vali-
dated FMRP targets (i.e., Dlg4, Map1b, CamK2a, and Arc) compared with
mRNAs considered as non-FMRP targets (PO, Glrb, ActB, and 28S) in Fmr1+/y
compared with Fmr1−/y neuron extracts as quantified by qRT-PCR.
RNA Isolation and Microarray Gene Expression Analysis. RNA from Fmr1+/y or
Fmr1−/y neuron inputs (InputFmr1+/y and InputFmr1−/y) or from CLIP samples
(CLIPFmr1+/y and CLIPFmr1−/y) were extracted by phenol/chloroform (vol/vol)
followed by chloroform/isoamyl alcohol (24:1) extraction and ethanol pre-
cipitated in the presence of 0.3 M sodium acetate. Quality of the RNAs was
controlled by using the Bioanalyzer 2100 (Agilent). RNAs used had RNA in-
tegrity number values ≥ 6.6. CLIP and Input RNAs were then used to prepare
biotinylated double-strand cDNA targets with the NuGEN Ovation Pico WTA
System V2 Kit (catalog no. 3302) followed by the NuGEN Encore Biotin
Module Kit (catalog no. 4200), according to manufacturer recommenda-
tions. After fragmentation and end-labeling, 2 μg of cDNAs was hybridized
for 16 h at 45 °C on GeneChip Mouse Gene 1.0 ST arrays (Affymetrix) in-
terrogating 28,853 genes (26,166 RefSeq transcripts). The chips were washed
and stained in the GeneChip Fluidics Station 450 (Affymetrix) and scanned
with the GeneChip Scanner 3000 7G (Affymetrix) at a resolution of 0.7 μm.
Raw data (.CEL Intensity files) were extracted from the scanned images by
using the Affymetrix GeneChip Command Console (Version 3.2). CEL files
were further processed with Affymetrix Expression Console software (Ver-
sion 1.1) to calculate probe set signal intensities using Robust Multiarray
Average algorithms with default settings. On mouse Gene 1.0 ST arrays, the
majority of genes are represented by one unique probe set, composed of
∼27 probes spread across the full length of the gene, giving a single signal
intensity value. A minority of genes on the array are interrogated by several
probe sets. For those genes, we used the median of all probe set signal in-
tensity values as a measure of their expression. Thus, only one fold change
value was calculated for each gene on the array as the ratio of the signal intensity
between Fmr1+/y and Fmr1−/y conditions (FC_adjusted in Dataset S1, raw data can
be accessed at www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51649). The
P value for probe sets signal intensity change between conditions was de-
termined by using the Significance Analysis of Microarrays test (49) (n = 5
biological replicates; i.e., one microarray per independent CLIP experiment
per biological replicate).
cDNA Synthesis and qRT-PCR Validation of RNAs with Best CLIP Scores. The first
strand cDNA was performed with SuperScript II Reverse Transcriptase kit
(Invitrogen) following manufacturer instructions. A total of 0.5 μg of RNA
from inputs or one-fourth from CLIP RNAs were used with gene-specific
primer mix (2 pmol each; see Table S1 for primer sequences). Primers were
validated with standard dilution curve on Fmr1+/y RNA input before quan-
tification of mRNA levels with a Lightcycler 480 (Roche). qRT-PCR was per-
formed on cDNA dilutions of 1/500 for ribosomal RNA and 1/4 for other
genes in the presence of 7.5-pmol primers with QuantiTect SYBR Green PCR
Master Mix (Qiagen). For CLIP experiments, two technical replicates were
performed for at least three biological replicates for 43 different genes. Fold
change between CLIPFmr1+/y and CLIPFmr1−/y was determined by using the fol-
lowing method: mean2ΔCt [CtIP WT − Ctinput WT]/mean2ΔCt [CtIP KO − Ctinput KO].
Error rates were calculated with the following formula: square root((Fmr1+/y SD/
Fmr1−/y SD)2 + (fold change)2).
Brain Polyribosome Profiling. Brain from 10-d-old C57BL/6J Fmr1+/y or Fmr1−/y
mouse embryos were dissected and homogenized with 10 strokes of Dounce
homogenizer in 0.7 mL of ice-cold lysis buffer (50 mM Tris·HCl, pH 7.4,
100 mM KCl, 5 mM MgCl2, 1 mM DTE, 40 U/mL RNasin, and 1% Nonidet
P-40). Extracts were cleared by 18,000 × g 4 °C centrifugation for 15 min, and
supernatants were loaded on linear sucrose gradient 15–45% (wt/wt) in
buffer (50 mM Tris·HCl, pH 7.4, 100 mM KCl, and 5 mM MgCl2) in SW41
tubes. Gradients were centrifuged at 36,000 rpm for 2 h at 4 °C in a Beckman
SW41 rotor. Gradients were collected in 12 fractions of 1 mL by using peri-
staltic pump coupled to AKTA (GE) detector and collector apparatus. Frac-
tions were precipitated with 2 volumes of cold ethanol at −20 °C. Pellets
obtained after centrifugation at 20,000 × g for 20 min were washed with
80% cold ethanol and briefly dried and resuspended in 20 μL of water. Total
RNAwas extracted from each fraction by acidic phenol/chloroform (1:1 vol/vol)
followed by a chloroform extraction and an ethanol precipitation. RNA was
resuspended in 20 μL of water, and its quality was checked on a 10th of the
material by electrophoresis in 1% agarose gel with ethidium bromide. cDNA
synthesis and qRT-PCR were performed as described above.
Neuron Treatments. mGluRI agonists DHPG resuspended in DMSO (Tocris) or
Quis resuspended inwater (Tocris) were applied on neurons at concentrations
of 100 and 5 μM, respectively, for 10 min at 37 °C at 8 DIV. DGK inhibitors
R59022 (DGK Inhibitor I; Calbiochem) and R59949 (DGK Inhibitor II; Calbio-
chem) were applied at concentrations of 3 and 0.2 μM each for 15 min at
37 °C prior an eventual mGluRI treatment.
PA Profiling by LC–MS/MS. Neurons of 8 DIV cultures (treated or not) from
a single six-well plate well were washed twice with cold PBS 1× and lysed
in cell extraction buffer (FNN0011; Invitrogen) supplemented with prote-
ase inhibitors (complete protease inhibitor mixture; Roche) and PMSF
(1 mM) for 30 min, on ice, with vortexing at 10-min intervals. Afterward,
neuron extracts were centrifuged for 18,000 × g for 10 min, and proteins
were quantified by the Bradford method to normalize samples. Total lipids
were extracted by the method of Bligh and Dyer (50). Typically, extracts were
mixed with chloroform:methanol (4:1), vortexed for 10 s, and left under
agitation for 1 h at 4 °C. After 5-min centrifugation at 18,000 × g, organic
phase was recovered and used for MS analyses. The organic phase (150 μL)
was analyzed by UPLC/MS/MS (Acquity UPLC System; Waters Corp.) coupled
to a Quattro Premier XE triple Quadrupole MS System; Waters Micromass).
Column was a Waters Acquity UPLC BEH Amide column (2.1 mm × 100 mm,
1.7-μm particle size) together with an Acquity UPLC BEH Amide precolumn
(2.1 mm × 5 mm, 1.7-μm particle size). Temperature of column oven was
28 °C, and injection volume was 3 μL. Eluents were acetonitrile, ammonium
hydroxide (99.5%:0.5%) (vol/vol) (A) and acetonitrile, water, and ammonium
hydroxide (80%:19.5%,0.5%) (vol/vol) (B). The flow rate was 0.4 mL/min.
Elution was as follows: 93% (vol/vol) A for 2 min. The gradient was as follows
(vol/vol): 93% A to 60% A in 1 min, 60% A to 50% A in 0.5 min, and 50% A
to 40% A in 1.5 min. Then the composition of the mobile phase was
returned to the initial conditions as follows (vol/vol): 40% A to 50% A in
2 min, 50% A to 80% A in 2.5 min, and 80% A to 93% A in 0.5 min. The 93%
A was maintained during 2 min. UV spectra were recorded from 200 to
500 nm. The system was run by Mass-Lynx software (Version 4.0). The ESI source
was used in positive and negative mode with a capillary voltage of 3.4 kV, RF
lens at 0 V, resolution (LM1, HM1, LM2, and HM2) 15, and ion energy 1 and
2:0.5. Source and desolvation temperatures were 135 °C and 400 °C. Flow
rates of nitrogen for nebulizer and desolvation were 50 and 900 L/h. Pres-
sure of the argon collision gas was 3.0 × 10−3 mbar. Full-scan, selected ion
recording, and daughter scan mode were used for qualitative analyses.
Quantitative PA analyses were made based on MS/MS MRM as described
(51). Briefly, MRM transitions for each individual PA were determined based
on PA standards obtained from Avanti Polar Lipids. The PAs were identified
as deprotonated parent ions [M-H−], and cone energy was optimized for
each PA and set to 44 V. The predominant daughter fragment ions were
then used for quantitative MRM analysis. After optimization, the collision
energy was set to 44 V. MRM transitions and specific retention times were
used to selectively monitor PA. Data acquisition and analysis were per-
formed with the MassLynx software (Version 4.1) running under Windows
XP professional on a Pentium PC.
DAG Measurements by LC–MS/MS. Neuron lysates from one six-well plate well
(prepared as for PA) and ±80 mg of postmortem human brain samples
(males, aged between 57 and 78, with one FXS aged 25) ground in a liquid
nitrogen cooled mortar were extracted with 2 mL of chloroform/methanol
2/1 (vol/vol), 1 mL of water, and 10 μL of synthetic internal standard (DAG
15:0/15:0) from Sigma Aldrich, sonicated for 30 s, vortexed, and centrifuged.
The lower organic phase was transferred to a new tube, and the upper
aqueous phase was reextracted with 2 mL of chloroform. Organic phases
were combined and evaporated to dryness under nitrogen. Lipid extracts
were resuspended in 50 μL of eluent A, and a synthetic internal lipid stan-
dard (DAG 17:0/17:0) from Nu-Check Prep was added. LC-MS/MS (MRM
mode) analyses were performed with mass spectrometer model QTRAP 5500
(ABSciex) coupled to a LC system (Ultimate 3000; Dionex). Analyses were
achieved in positive mode. Nitrogen was used as curtain gas (set to 20), gas1
(set to 25), and gas2 (set to 0). Needle voltage was at +5,500 V without
needle heating; the declustering potential was set at +86 V. The collision
gas was also nitrogen; collision energy was adjusted to +34 V. Dwell time was
set to 3 ms. Reversed-phase separation was carried out at 30 °C on a Phe-
nomenex Luna 3u C8 column (150 mm × 1 mm, 3-μm particle size, 100-Å pore
size). Eluent A was ACN/MeOH/H2O (19/19/2, vol/vol/vol) +0.2% formic acid
+0.028% NH4OH, and eluent B was isopropanol +0.2% formic acid +0.028%
NH4OH. The gradient elution programwas 0–5min, 15% (vol/vol) B; 5–35min, 15–
40% B; 35–40 min, 80% B; and 40–55 min, 15% B. The flow rate was 40 μL/min,
and 3-μL sample volumes were injected. The relative levels of DAG species
were determined by measuring the area under the peak, determined by using
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MultiQuant software (Version 2.1; ABSciex) and normalizing to the area of the
DAG internal standard.
AAV Vector Construction. A shRNA designed to target Dgkκ (shRNA Dgkκ
5′-GGAATGCACTACTGGTATTCC) and the selected shRNA–scramble sequence
(5′-GCGCTTAGCTGTAGGATTC) that has no match in silico in the mouse ge-
nome were cloned under the control of the mU6 promoter into a pAAV-
MCS–derived plasmid expressing enhanced green fluorescent protein (EGFP)
under the control of a CMV promoter. Overexpression of Dgkκ was achieved
by cloning HA-tagged Dgkκ under the control of the hSynapsin promoter
replacing EGFP in the control plasmid pENN.AAV.hSynapsin.EGFP.RBG (pro-
vided by the Penn Vector Core at University of Pennsylvania, Philadelphia).
Recombinant adeno-associated virus serotype 9 (AAV9) coexpressing EGFP and
shRNA (AAV9-EGFP-shRNA-Dgkκ and control AAV9-EGFP-shRNA-scramble), as
well as AAV9 expressing HA-Dgkκ or EGFP (AAV9-hSyn-HA-Dgkκ and control
AAV9-hSyn-EGFP) were generated. AAV production was carried out by using
the AAV Helper-Free system (Agilent Technologies) with some modifications.
AAV9 vectors were generated by triple transfection of 293T/17 cell line using
either pAAV-EGFP-shRNA-Dgkκ or pAAV-EGFP-shRNA-scramble, pAAV-hsy-
napsin-HA-Dgkκ or pENN.AAV.hSynapsin.EGFP.RBG together with pAAV2/9
(Penn Vector Core) containing cap genes of AAV serotype 9 and pHelper. Two
days after transfection, cells were collected, lysed by three freeze/thaw cycles
in dry ice-ethanol and 37 °C baths, further treated with 100 U/mL Benzonase
(Novagen) for 30 min at 37 °C, and clarified by centrifugation. Viral vectors
were purified by iodixanol (Optiprep; Axis Shield) gradient ultracentrifugation
followed by dialysis and concentration against PBS containing 0.5 mM MgCl2
using centrifugal filters (Amicon Ultra-15 100 K). Viral particles were quanti-
fied by real-time PCR using a linearized standard plasmid pAAV-EGFP. To
achieve comparable working concentrations, viruses were diluted to a final
concentration of 5 × 1012 viral genomes per mL and stored at −80 °C until use.
Slice Culture Transfection and Imaging. Hippocampal organotypic slice cul-
tures (400-μm thick) were prepared from postnatal 5- to 6-d-old C57BL/6
Fmr1+/y or its Fmr1−/y littermate mice by using a protocol approved by the
Geneva veterinary office and maintained under culture conditions as de-
scribed (52). Transfection was carried out at 7 DIV with a biolistic method
(Helios Gene Gun; Bio-Rad) using gold beads coated with mRFP and either
pAAV-EGFP-shRNA-Dgkκ, pAAV-EGFP-shRNA-scramble, pAAV-hSynapsin-EGFP,
or pAAV-hSynapsin-Dgkκ. Repetitive confocal imaging was performed as de-
scribed (52). Briefly, dendritic segments of CA1 transfected neurons (30–40 μm
in length) were imaged from 12 to 15 DIV (at 0, 5, 24, 48, and 72 h) by using an
Olympus Fluoview 300 system, and analysis of the Z-stacked images obtained
was performed by using Osirix software.
Slice Infection and Electrophysiology. To investigate the functional role of
Dgkκ, the CA1 area of hippocampal organotypic slices was infected at 4 DIV
by placing a small piece of porous membrane on top of the CA1 area (White
FHLC Membrane, Filter type 0.45 μm; EMD Millipore) injected with 0.3 μL (5 ×
1012 viral genomes per mL) of either AAV9-EGFP-shRNA-Dgkκ or AAV-EGFP-
shRNA-scramble viruses. The injection of the porous membrane was carried out
by using a picospritzer (Toohey). The porous membrane was removed after 1 h
and the slices maintained under culture conditions. The efficacy of infection was
verified in all slices before the electrophysiological recordings by checking the
level and area of expression of GFP. Infected slice cultures were tested electro-
physiologically at DIV 7–8 for LTD and DIV14–15 for LTP and placed in an
interface-type of recording chamber and continuously perfused with a
medium containing (in mM): NaCl 124, KCl 1.6, CaCl2 2.5, MgCl2 1.5,
NaHCO3 24, KH2PO4 1.2, glucose 10, and ascorbic acid 2; saturated with
95% O2 and 5% CO2 (pH 7.4; temperature 31 °C). EPSPs were evoked by
stimulation of a group of CA3 cells by using a stimulating electrode made of
twisted nichrome wires, and responses were recorded in the CA1 stratum region
by using a glass patch pipette. LTD was induced by a low-frequency stimulation
protocol (900 pulses at 5 Hz), whereas LTP was induced by TBS (3 × 5 bursts at
5 Hz composed each of four pulses at 100 Hz) as in ref. 53. EPSPs were recorded
by using IGOR software, and variations in response size were assessed by mea-
suring EPSP slopes and expressed as percent of baseline values.
Stereotaxic Surgery and AAV Injections.Mice (C57BL/6J) were deeply anesthetized
with ketamine/xylazine (Virbac/Bayer, 100/10 mg/kg, 10 mL/kg, intraperitoneal)
dissolved in sterile isotonic saline (NaCl 0.9%) and mounted onto a stereotaxic
frame (Unimecanique). AAV9-EGFP-shRNA-Dgkκ or AAV-EGFP-shRNA-scramble
(5 × 1012 viral genomes per mL) was injected bilaterally into the striatum (co-
ordinates relative to bregma: anterior-posterior + 0.7 mm; lateral = ±1.5 mm;
vertical −4.5 mm) according to the mouse brain atlas (56). A volume of 1.5 μL of
AAV vectors per site of injection was delivered bilaterally with a slow injection
rate (0.1 μL/min) through a 30-gauge stainless steel cannula connected to an
infusion pump. After each injection was completed, the injector was left in place
for an additional 10 min to ensure optimal diffusion and minimize backflow
while withdrawing the injector. Behavioral experiments were conducted 4 wk
after AAV injections to allow sufficient time for viral transduction and Dgkκ
expression. Effective gene knockdown was assessed by qRT-PCR (Fig. S3D).
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